Cipla Appoints New SMPs as Umang Vohra Steps Down
Mumbai: Cipla Limited has announced key leadership changes following a Board meeting held on March 30, 2026, marking a significant transition in its executive structure.
The company has designated Saurabh Gambhir, Head – Strategy and Mergers & Acquisitions (Global), and Satyavan Manikani, Chief Portfolio Head (Global), as Senior Management Personnel (SMP), effective April 1, 2026. Both will report directly to the newly appointed Managing Director and Global Chief Executive Officer, Achin Gupta.
Saurabh Gambhir will continue to lead Cipla’s global strategic initiatives, including mergers and acquisitions and digital transformation programs.
With prior experience at Emcure Pharmaceuticals and Intas Pharmaceuticals, he has played a crucial role in shaping the company’s long-term growth strategy and strengthening its global positioning.
Satyavan Manikani, who joined Cipla in February 2022, has been instrumental in driving portfolio strategies across therapeutic segments. He has previously held leadership roles at USV Limited, Gufic Biosciences, Alkem Laboratories, and Ranbaxy Laboratories, contributing significantly to portfolio optimization and successful product launches.
Meanwhile, Umang Vohra has stepped down as Director of the company with effect from April 1, 2026, upon completion of his tenure as Managing Director and Global CEO on March 31, 2026.
In his resignation note, Vohra expressed gratitude for his decade-long association with Cipla, highlighting the organization’s commitment to patient-centric innovation and acknowledging the support of the Board and Chairman Dr Y K Hamied. He also conveyed his best wishes for the company’s continued growth and success.
